SecBot SecBot

GRI

GRI Bio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001824293 Biotech & Drug Discovery
$1.58 +0.08 (+5.33%)
Oct 27 4:00 PM ET · prev $1.50
Market cap
$3.2M
Nano cap
Consensus
Buy
83% Buy or better · 6 analysts
Median target
$18.50
+1071% · range $10.00–27.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.84
1 year
−97.1%
from $54.32 · Oct 28
30 days
−24.8%
from $2.10
52-week range
$1.38–59.92
−97% from high · low Jul 31
Avg volume 20D
44.1K
shares / day
Short interest
66.1K
≈3.0% of shares · −4.8%
Days to cover
1.6
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · latest
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 12, 2026
Strongest BULLISH GRI Bio, Inc. announced that the FDA has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    5 of 6 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.080 → −$0.840 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.8% to 66.1K shares. 1.6 days to cover, ≈3.0% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM4,920$8.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts
Buy 83% rate it Buy or better
Strong Buy1Buy4Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +1071%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 21, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 1, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.84
EPS estimate, this quarter
+22%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.84-$0.93–-$0.75+0.0%$0.00
Next Q-$0.82-$0.91–-$0.74+0.0%$0.00
Current FY-$3.90-$4.13–-$3.66+0.0%$0.00
Next FY-$2.00-$3.79–-$0.21+0.0%$0.00
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Other
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translatin
Jun 30, 2026 Inst.
UBS Group AG — TRIM
4,920 shares ($8.7K)
Jun 18, 2026 SEC
GRI Bio, Inc. announced that the FDA has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of…
8-K — Impact 6/10
May 14, 2026 SEC
GRI Bio reported Q1 2026 financial results with a net loss of $2.0M (improved from $3.0M in Q1 2025) and cash of…
8-K — Impact 5/10

Short side

FINRA· Oct 15, 2026
66,115
shares short
-4.8%
vs prior settlement
1.6
days to cover
≈3.0%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
GRI Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 28, 2026
Press release
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel…
Sep 8, 2026
Press release
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition…
Aug 27, 2026
Company news
GRI Bio Featured in "Why Now" On-Demand Video Webcast
Video webcast now available here
Aug 24, 2026
Press release
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing…
Aug 12, 2026
Earnings date
GRI Q2 2026 Earnings Scheduled — 2026-08-12

SecBot reports

2 filings · 1 bullish · 0 bearish · 1 neutral
All GRI filing & press-release reports (2)